Association of potential salivary biomarkers with diabetic retinopathy and its severity in type-2 diabetes mellitus: a proteomic analysis by mass spectrometry

Chin Soon Chee, Khai Meng Chang, Mun Fai Loke, Voon Pei Angela Loo, Visvaraja Subrayan

Aim/hypothesis The aim of our study was to characterize the human salivary proteome and determine the changes in protein expression in 2 different stages of diabetic retinopathy with type-2 diabetes mellitus: (1) with non-proliferative diabetic retinopathy (NPDR) and (2) with proliferative diabetic retinopathy (PDR). Type-2 diabetes without diabetic retinopathy (XDR) was designated as control. Method In this study, 45 saliva samples were collected (15 samples from XDR control group, 15 samples from NPDR disease group and 15 samples from PDR disease group). Salivary proteins were extracted, reduced, alkylated, trypsin digested and labeled with iTRAQ before analyzing by Orbitrap fusion tribrid mass spectrometer. Proteins annotation, fold change calculation and statistical analysis were interrogated by Proteome Discoverer. Biological pathway analysis was performed by Ingenuity Pathway Analysis. Data are available via ProteomeXchange with identifiers PXD003723-PX003725. Results A total of 315 proteins were identified from the salivary proteome and 119 proteins were found to be differentially expressed. The differentially expressed proteins from the NPDR disease group and the PDR disease group were assigned to respective canonical pathways indicating increased LXR/RXR activation, FXR/RXR activation, acute phase response signaling, sucrose degradation V and regulation of actin-based motility by Rho in the PDR disease group compared to the NPDR disease group Conclusions/Interpretation Progression from non-proliferative to proliferative retinopathy in type-2 diabetic patients is a complex multi-mechanism and systemic process. Furthermore, saliva was shown to be a feasible alternative sample source for diabetic retinopathy biomarkers.
Association of potential salivary biomarkers with diabetic retinopathy and its severity in type-2 diabetes mellitus: a proteomic analysis by mass spectrometry

Chin Soon Chee¹, Khai Meng Chang¹, Mun Fai Loke², Angela Voon Pei Loo¹*, Visvaraja Subrayan¹

(1) Department of Ophthalmology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia

(2) Department of Medical Microbiology, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia

*Corresponding author:
Angela Voon Pei Loo
Department of Ophthalmology
Faculty of Medicine
University of Malaya
50603 Kuala Lumpur
Malaysia
Phone: +603-79492060
Email: voonpei@um.edu.my
Abstract

Aim/hypothesis The aim of our study was to characterize the human salivary proteome and determine the changes in protein expression in 2 different stages of diabetic retinopathy with type-2 diabetes mellitus: (1) with non-proliferative diabetic retinopathy (NPDR) and (2) with proliferative diabetic retinopathy (PDR). Type-2 diabetes without diabetic retinopathy (XDR) was designated as control.

Method In this study, 45 saliva samples were collected (15 samples from XDR control group, 15 samples from NPDR disease group and 15 samples from PDR disease group). Salivary proteins were extracted, reduced, alkylated, trypsin digested and labeled with iTRAQ before analyzing by Orbitrap fusion tribrid mass spectrometer. Proteins annotation, fold change calculation and statistical analysis were interrogated by Proteome Discoverer. Biological pathway analysis was performed by Ingenuity Pathway Analysis. Data are available via ProteomeXchange with identifiers PXD003723-PX003725.

Results A total of 315 proteins were identified from the salivary proteome and 119 proteins were found to be differentially expressed. The differentially expressed proteins from the NPDR disease group and the PDR disease group were assigned to respective canonical pathways indicating increased LXR/RXR activation, FXR/RXR activation, acute phase response signaling, sucrose degradation V and regulation of actin-based motility by Rho in the PDR disease group compared to the NPDR disease group.

Conclusions/Interpretation Progression from non-proliferative to proliferative retinopathy in type-2 diabetic patients is a complex multi-mechanism and systemic process. Furthermore, saliva was shown to be a feasible alternative sample source for diabetic retinopathy biomarkers.

Keywords: Diabetic retinopathy, salivary proteome, iTRAQ, LC/MS

Abbreviations

ACTB Actin, cytoplasmic 1
AGC Automatic gain control
AGE Glycation end-products
ANXA1 Annexin A1
APOA1 Apolipoprotein A-I
C3 Complement 3
CAMP Cathelicidin antimicrobial peptide
CAP1 Adenylyl cyclase-associated protein 1
| 76  | CLU   | Clusterin             |
| 77  | ELANE | Neutrophil elastase   |
| 78  | ENO1  | Alpha-enolase isoform 1 |
| 79  | EZR   | Ezrin                |
| 80  | FXR/RXR | Farnesoid X receptor/Retinoid X receptor |
| 81  | GAPDH | Glyceraldehyde-3-phosphate dehydrogenase isoform 2 |
| 82  | GO    | GO annotation        |
| 83  | GSN   | Gelsolin isoform d   |
| 84  | HBA1/HBA2 | Hemoglobin subunit alpha |
| 85  | HCD   | Higher-energy collisional dissociation |
| 86  | HP    | Haptoglobin isoform 2 |
| 87  | HSPA1A/HSPA1B | Heat shock 70 kDa protein 1A/1B |
| 88  | HSPA8 | Heat shock cognate 71 kDa protein isoform 1 |
| 89  | iBRB  | Inner blood retina barrier |
| 90  | IPA   | Ingenuity Pathway Analysis |
| 91  | iTRAQ | Isobaric tag for relative and absolute quantitation |
| 92  | kV    | kilovolt             |
| 93  | LC-MS | Liquid chromatography- mass spectrometer |
| 94  | LCN1  | Lipocalin-1 isoform 1 |
| 95  | LCN2  | Neutrophil gelatinase-associated lipocalin |
| 96  | LCP1  | Plastin-2            |
| 97  | LDHA  | L-lactate dehydrogenase A chain isoform 3 |
| 98  | LTF   | lactotransferrin isoform 1 |
| 99  | LXR/RXR | Liver X receptor/ Retinoid X receptor |
| 100 | MIF   | Macrophage migration inhibitory factor |
| 101 | MMP9  | Matrix metalloproteinase-9 |
| 102 | MPO   | Myeloperoxidase       |
| 103 | MRP8/14 | Myeloid-Related Protein-8/14 |
| 104 | MS    | Mass spectrometry    |
| 105 | NPDR  | Type-2 diabetes mellitus with non-proliferative diabetic retinopathy |
| ID  | Gene Symbol | Description                                      |
|-----|-------------|--------------------------------------------------|
| PDR | Type-2 diabetes mellitus with proliferative diabetic retinopathy |
| PKM | Pyruvate kinase isozymes M1/M2 isoform c |
| PLTP| Phospholipid transfer protein isoform a |
| PRDX1| Peroxiredoxin-1 |
| PRTN3| Profilin-1 |
| S100A8| S100 calcium-binding protein A8 |
| S100A9| S100 calcium-binding protein A9 |
| SERPINA1| Alpha-1-antitrypsin |
| SIM | Single ion monitoring |
| SLPI | Antileukoproteinase |
| TIMP1| Metalloproteinase inhibitor 1 |
| TLR-4| Toll-like receptor-4 |
| TPM3| Tropomyosin alpha-3 chain isoform |
| XDR | Type-2 diabetes mellitus without diabetic retinopathy |
**Introduction**

Early onset of type-2 diabetes mellitus has been devastating and a major epidemic across the world. Report shows that 7% of newly diagnosed type-2 diabetic patients in the U.S. have been diabetic for approximately 4-7 years before diagnosis (Rao et al. 2009). There is a very low global awareness and precaution on how to prevent type-2 diabetes. Patients with prolonged type-2 diabetes without proper consultation and medication have a higher probability of developing complications such as diabetic retinopathy which can eventually lead to blindness.

Diabetic retinopathy is one of the most common and severe microvascular complications of type-2 diabetes. Symptoms of diabetic retinopathy were retinal ischemia and increased retinal vascular permeability which leads to vision loss or blindness ultimately. Diabetic retinopathy could be classified into two main stages: non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) in terms of the severity. The NPDR patients had lesions on the eye vasculature layer and vision would be lost if there was fluid in the central portion of the eyes (Csosz et al. 2012). PDR was literally characterized by pathological retinal vascular leakage (macular edema) and retinal neovascularization (Gao et al. 2008). There are several studies reported on the factors related to pathogenesis of PDR (Tarr et al. 2013), e.g., vascular endothelial growth factor for the proliferation and propagation of blood vessels in eyes, angiotsin-converting enzyme, insulin-like growth factor, angiotensin, erythropoietin, placenta growth factor, advanced glycation end product, and antiangiogenic factors like pigment epithelium-derived factor.

The noninvasive nature and simple collection allows repetition and multiple collection of saliva that can potentially aid in early diagnosis, monitoring disease progression, or treatment responses with minimally trained personnel. This advantage of using saliva attracts investigators who are looking for an alternative body fluid to simplify diagnostic procedures (Giusti et al. 2007a; 2007b; Hu et al. 2007a; Peluso et al. 2007). Secretions from salivary glands, oral mucosa, periodontium, and oral microbiota all contribute to the final content of saliva. Saliva, a complex balance from local and systemic sources, allows for applications in the diagnosis not only for salivary gland disorders but also for oral diseases and systemic conditions (Caporossi et al. 2010; Good et al. 2007; Hu et al. 2007b; Lee et al. 2009). In our study, saliva samples from XDR, NPDR and PDR patient groups are selected as a diagnostic fluid to study the salivary proteome. Saliva offers several advantages over vitreous humor, tears and serum. The availability of saliva make it the simplest and non-invasive way of body fluid collection allowing repetitive collection. Saliva collection decreases the risk of contracting infectious diseases compared to other body fluids collection and it is convenient to obtain saliva from children or handicapped patients, in whom blood sampling could be inconvenient. Saliva is an ideal body fluid for the purpose of biomarker identification based on several decent studies. Castagnora et al (Castagnola et al. 2011) reported that there was existence of specific salivary biomarkers associated with a health or disease state. In the meanwhile, Shinkai et al (Shinkai et al. 2004) also reported that there was an altered saliva composition in type-2 diabetic patients. Hence, it is important to investigate the salivary proteome profiles for diabetic retinopathy complications. Moreover, biomarkers from salivary proteome of diabetic retinopathy are yet to be discovered.

In recent years, advancement in proteomic technology has invented plenty of instruments for proteomics research. A sophisticated mass spectrometer, the Orbitrap fusion tribrid mass spectrometer is used in our study to achieve our objective. The Orbitrap fusion tribrid mass
spectrometer, comprises of a mass filter, a collision cell, a high-field Orbitrap analyzer and a
dual cell linear ion trap analyzer, offers high MS² acquisition speed of 20 Hz (Senko et al. 2013).
We believe that this new system, with its fast scan rate, could provide more comprehensive
proteome analysis within shorter time. The development of higher energy collision-induced
dissociation (HCD) in the LTQ-Orbitrap has also overcome the 1/3 rule limitation that restricts
the analysis of product ions with m/z values less than 25–30% of the precursor ion in traditional
ion-trap instruments (Rauniyar et al. 2014). Limitations with analyzing biological samples of
complex nature, such as the salivary proteome, are the masking of low-abundance proteins by the
preponderance of a small number of highly abundant salivary proteins and the high dynamic
range of such proteome that precludes the use of conventional proteomic strategies (Hu et al.
2005; 2007a). A method that has been proposed to largely overcome these deficits is isobaric
labeling (iTRAQ: isobaric tags for absolute and relative quantitation) (Casado-Vela et al. 2010;
Rauniyar et al. 2014). These isotope tags permit ready discrimination by mass spectrometry,
thereby permitting comparative quantification to a reference sample in a multiplex manner and
the examination of different samples in a single mass spectrometric analysis with good
quantification precision. Hence, the ratio cutoff applied for significant protein change via the
iTRAQ approach is lower than the cutoff applied for the label-free quantification approach
(Rauniyar et al. 2014). This is the first attempt to analyze the salivary proteome profiles of type-2
diabetes complicated with diabetic retinopathy using the high resolution and accurate mass
Orbitrap fusion tribrid mass spectrometer.

Methodology

Sample collection and processing

Saliva sample from 45 subjects with type-2 diabetes mellitus were collected. Subjects for this
study were recruited from patients who visited the Eye clinic at the University of Malaya
Medical Center (UMMC) during the period between November 2013 and April 2014. Patients
older than 45 years old diagnosed with type-2 diabetes for more than 5 years with or without
diabetic retinopathy were included in this study. All the patients were on oral medication for
glycemic index control and /or dyslipidemia (none of them were on insulin therapy). The
following patients were excluded from the study: (1) patients who had oral surgery or treatment
within the past 3 months; (2) patients who had active gum bleeding; (3) patients with dry mouth
(e.g. Sjögren’s syndrome); (4) patients who had recent oral injury; (5) patients with history of
malignancy, autoimmune diseases, Hepatitis/ HIV infection; (6) patients on any types of eye
drops for active eye disease (e.g. glaucoma, conjunctivitis); (7) patients who had significant
ocular medium opacities such as cataract or hazy cornea; (8) patients who had intravitreal
injection and/or retinal laser treatment prior to diagnose for diabetic retinopathy; (9) patients
with quiescent PDR and (10) smokers. Patients were classified by their severity of diabetic
retinopathy according to the International Clinical Classification System for Diabetic
Retinopathy and Diabetic Macular Edema by American Academy of Ophthalmology (Wilkinson
et al. 2003). Diabetic retinopathy was graded through clinical fundus examination photography
by two independent eye specialists. Subjects were grouped into three groups based on their
clinical presentation: (1) type-2 diabetes without diabetic retinopathy (XDR) as control, (2) type-2
diabetes with non-proliferative diabetic retinopathy (NPDR) and (3) type-2 diabetes with
proliferative diabetic retinopathy (PDR) (Table 1). PDR patients with active neovascularization were included.

Subjects fasted overnight for at least 8 hours (except for drinking) prior to the collection of saliva samples. They were instructed to avoid drinks containing caffeine and alcohol for 12 hours and avoid vigorous physical activity for 4 hours prior to sample collection. In addition, they were also reminded to avoid brushing teeth 1 hour prior to sample collection and avoid applying lipstick. Saliva samples were collected between 9-10 a.m. The subjects were asked to rinse their mouths thoroughly with sterile water 10 minutes before sample collection, then to tilt their heads forward and allow saliva to flow into a sterile centrifuge tube until 5mL of saliva was collected. Saliva samples were spun at 8000 ×g for 20 min at 4 °C to spin down nuclei, cell debris and bacteria cells. The supernatant was then kept at -20 °C for subsequent analysis.

This study was approved by the Medical Ethics Committee of UMMC (Reference number: 1017.28) and written informed consent was obtained from the patients prior to samples collection.

Table 1 Demographic of subjects.

Proteins extraction

Salivary protein was extracted by acetone precipitation method as described by Vitorino et al (Vitorino et al. 2012) with modification. Saliva samples were precipitated by mixing with six volumes of pre-chilled acetone (Grade AR) (Friedemann Schmidt, Parkwood, Perth, Australia) and mixed by vortexing. Each sample was allowed to stand overnight at 4 °C. After incubation, all samples were centrifuged at 12000 ×g for 30 min. The supernatant and pellet were separated. The pellet was dried at room temperature.

Protein concentration

Protein concentration was determined using Bradford assay (Bio-Rad, Hercules, California USA) with bovine serum albumin (BSA) as standard (Bradford 1976). Protein standards and tests were prepared in triplicate.

Reduction, alkylation and trypsin digestion of salivary proteins

Reduction, alkylation and trypsin digestion of salivary proteins were carried out according to the method described by Ross et al (Ross et al. 2004) with modification. Briefly, 50 μg of salivary protein was suspended in 100 mmol/l triethy lammonium bicarbonate (pH 8.5) (Sigma-Aldrich, St. Louis, Missouri, USA) and vortex to make sure the pellet was completely dissolved. Protein reduction was carried out by adding 10 mmol/l tris-(2-carboxyethyl)-phosphine (Sigma-Aldrich, St. Louis, Missouri, USA) and incubated at 60 °C for 60 min. Reduced protein was subsequently alkylated with 20 mmol/l iodoacetamide (Bio-Rad, Hercules, California, USA) in the dark for 60
min at room temperature. Finally, the protein samples were digested with 1 μg of mass
spectrometry grade porcine trypsin (Calbiochem, La Jolla, California, USA) at 37 ºC for 16-18
hours. The reaction was terminated by adding trifluoroacetic acid (Sigma-Aldrich, St. Louis,
Missouri, USA) to the final concentration of 5% (v/v).

**Isobaric tag for relative and absolute quantitation (iTRAQ) labeling
of salivary peptides**

Digested peptides samples were labeled using the iTRAQ 8Plex Multiplexing kit (AB Sciex,
Foster city, California, USA) according to the manufacturer’s protocol. Peptides from XDR,
NPDR and PDR patient groups were labeled with isobaric tags 113, 114 and 115 respectively at
room temperature for 4 hours. The reaction was quenched with 20 mmol/l Tris (pH 8.0) (Sigma-
Aldrich, St. Louis, Missouri, USA). The contents of each iTRAQ reagent labeled sample tubes
were combined.

**Peptide purification and concentration**
Pierce C18 Spin Column (Thermo Scientific, Rockford, Illinois, USA) was used to purify and
concentrate the labeled peptides according to the manufacturer’s protocol.

**Liquid chromatography-mass spectrometer (LC-MS) analysis**
Ten micrograms of salivary digest were separated on the EASY-nLC 1000 (Thermo Scientific,
San Jose, California, USA) using the Acclaim PepMap C\textsubscript{18} (3 μm, 75 μm x 50 cm) column
(Thermo Scientific, San Jose, California, USA). Solvent A was HPLC-grade water with 0.1%
formic acid, and solvent B was HPLC grade acetonitrile with 0.1% (v/v) formic acid.
Separation was performed with stepwise gradient (5-30% B for 185 min, 30-50% B for 20 min,
50-95% B for 20 min) at 300 nl/min over 225 min. MS data was generated using an Orbitrap
fusion tribrid mass spectrometer (Thermo Scientific, San Jose, California, USA) operated with -
2.5 kV (positive ions) applied to the central electrode. The mixture of isotopolog peptides were
analyzed by combining scan events from two SIM modes. The first full time scan mode (MS)
employed a scan range (m/z) of 380-2,000, Orbitrap resolution of 120,000, target automatic gain
control (AGC) values of 200,000 and a maximum injection time of 50 milisec. The second scan
mode, HCD (high energy collisional dissociation)-MS/MS was performed at the Quadrupole
with the isolation width of 1.6 Th, HCD fragmentation with normalized collision energy of 35 %,
Orbitrap resolution of 30,000, target AGC values of 50,000, and a maximum injection time of 60
milisec. Only precursors with charge state 2–7 were subjected to MS\textsuperscript{2}. Monoisotopic precursor
selection and dynamic exclusion (70 sec duration, 10 ppm mass tolerance) were enabled.
Analysis was carried out with 3 technical replications.

**Data analysis**
The raw data was processed using Proteome Discoverer version 1.4 (Thermo Scientific, San Jose, California, USA). MS/MS spectra were searched with Sequest engine against Homo sapiens database using the following parameters: full trypsin digest with maximum 2 missed cleavages, fixed modification carbamidomethylation of cysteine (+57.021 Da), variable modification oxidation of methionine (+15.995 Da) and iTRAQ 8-plex modification of lysine and peptide N termini (+304.205 Da). Precursor mass tolerance was 10 ppm and product ions fragment ion tolerance was 0.02 Da. Peptide spectral matches were validated using percolator based on q-values at a 1% false discovery rate. iTRAQ ratio reporting was pair wise: NPDR/XDR (114/113) and PDR/XDR (115/113).

Bioinformatic analysis of differential expressed proteins.
Differentially expressed proteins from NPDR and PDR patient groups were further analyzed using Ingenuity Pathway Analysis (IPA version 8.8) (Qiagen, Redwood, California, USA) to statistically determine the functions and pathways associated with each of the individual proteins. Accession number for each of the proteins and the fold change between NPDR and PDR groups relative to XDR group were tabulated. IPA utilized the Ingenuity Pathways Analysis Knowledge Base (IPa KB), a manually curated database of protein interactions from the literature, for analysis. A fold change cut-off of 1.5 was set to identify significant differentially regulated proteins. A list of networks and functional and canonical pathways were generated and the significance of the associations was assessed with the Fisher’s exact test (p < 0.05).

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (Vizcaíno et al. 2016) partner repository with the dataset identifier sPXD003723- PXD003725.

RESULT

Based on the criteria that at least one unique peptide and a minimum of two peptides match for protein identification, 315 proteins could be identified from the salivary proteome. The mean percentage of peptide coverage was 35.17% ± 2.55 ranging from 1.72% to 87.67%. The overall salivary proteome was annotated using GO annotation analysis facilitated by Proteome Discoverer version 1.4 and ProteinCenter database. Salivary proteins were assigned according to three different classifications: cellular component classification, biological process classification and molecular function classification. Of which, 19% were cytoplasmic proteins, 19% were extracellular proteins, 12% were membrane proteins and 11% were proteins localized in the nucleus (Figure A in S1 figure). Metabolic proteins comprised 15% of the proteins identified, 13% were involved in regulation of biological process and 12% were proteins that respond to stimulus (Figure B in S1 figure). As high as 29% of the proteins were involved in protein binding, 18% showed catalytic activities and 11% was involved in metal ion binding (Figure C in S1 figure).
For quantitative analysis, only proteins with complete labeled peptides were considered. iTRAQ data was expressed in pair ratio: NPDR vs XDR (iTRAQ 114/iTRAQ 113) and PDR vs. XDR (iTRAQ 115/iTRAQ 113). Only those with fold-change < 0.5 or > 2 were considered to be differentially expressed. A total of 119 proteins were found to be differentially expressed. Fig. 1 illustrates the comparison of the log ratio of the relative intensity (NPDR/XDR; PDR/XDR) for proteins commonly found in XDR, NPDR and PDR disease groups. Fig. 2 presents the comparison of the log ratio of the relative intensity (NPDR/XDR; PDR/XDR) for proteins unique to XDR and NPDR or PDR disease groups. Among those that are differentially expressed, 1 protein was un-regulated in NPDR and PDR compared to XDR disease groups. Eighty-two proteins were increased in PDR compared to XDR disease groups but decreased in NPDR in comparison to XDR disease groups. Two proteins were down-regulated in NPDR compared to XDR disease groups but not detected in PDR disease group. The remaining 34 proteins were increased in PDR relative to XDR disease groups but not found in NPDR disease group.

Fig. 1 Log ratio of relative intensity (NPDR/XDR; PDR/XDR) for proteins commonly found in XDR, NPDR and PDR disease groups.

Fig. 2 Log ratio of relative intensity (NPDR/XDR; PDR/XDR or proteins found exclusively in NPDR and PDR disease groups.

A total of 117 salivary proteins were increased in PDR disease group relative to XDR disease group. Eighty-two increased salivary proteins in PDR disease group were decreased in NPDR disease group, 34 were not found in NPDR disease group and metalloproteinase inhibitor 1 precursor was increased in both PDR and NPDR disease groups. Table S1 lists the top 26 most up-regulated salivary proteins with a minimum fold change of 20 by relative protein abundance. Among the top 20 proteins that were increased in PDR disease group, 13% were predicted to respond to stimulus, 10% were predicted to regulate biological process, 9% were involved in metabolism, 8% were involved in cell organization and biogenesis and 8% were predicted to be involved in defense response (Figure B in S2 figure). Most of these proteins were predicted to have protein binding capability (28%) and 17% might have catalytic activity (Figure C in S2 figure). On the other hand, peroxiredoxin-1 and unconventional myosin-IXb isoform 2 were decreased in NPDR disease group (Table S2).

Twenty one interacting proteins and 1 highly increased protein (clusterin from NPDR disease group), together with 35 interacting proteins and 1 highly increased protein (tropomyosin alpha-3 chain isoform 2 from PDR disease group) (Table in S3 table) generated 3 protein-protein networks (Figure in S3 figure). Network (A) includes the diseases and functions of connective tissue disorders, immunological disease and inflammatory disease. Network (B) includes the diseases and functions of cellular movement, hematological system development and function and immune cell trafficking while Network (C) includes the diseases and functions of cellular growth and proliferation, cancer and carbohydrate metabolism. The top three canonical pathways with the highest –log (p-value) for NPDR disease group were LXR/RXR activation, glycolysis I and clathrin-mediated endocytosis signaling while for PDR group the pathways were LXR/RXR activation, glycolysis I and FXR/RXR activation. Comparison between the differentially
expressed proteins from NPDR and PDR disease groups in different canonical pathways indicated increased LXR/RXR activation, FXR/RXR activation, acute phase response signaling, sucrose degradation V and regulation of actin-based motility by Rho in PDR disease group compared to NPDR disease group (Fig 3).

Fig. 3 Canonical pathways comparative studies in differentially expressed proteins from NPDR and PDR groups.

Discussion

To the best of our knowledge, the salivary proteome of diabetic retinopathy has not yet been characterized. Among top increased proteins in the PDR group, 8% were predicted to be defense proteins and 9% were metabolic proteins suggesting that the expression of salivary defense and metabolic proteins is related to diabetic retinopathy. This is consistent with the report by Fernandez-Real and Pickup (Fernandez-Real & Pickup 2008) that defense response proteins were elevated in type-2 diabetic patients and this gradually led to surging of metabolic proteins. Most of these defense response proteins that were increased in PDR are involved with pro-inflammatory immune response and many had previously been reported to be associated with diabetes mellitus. Such defense response proteins include S100-A9 (Cabras et al. 2010), alpha-2-macroglobulin-like protein 1 (James et al. 1980), neutrophil elastase (Collier et al. 1989), alpha-1-antitrypsin (SERPINA1) (Kalis et al. 2010), cystatin-C (Reutens et al. 2013) and macrophage migration inhibitory factor (MIF) (Tashimo et al. 2004). Heterodimer of S100-A9 and S100-A8 known as myeloid-related protein-8/14 (MRP8/14) binds to receptor for advanced glycation end-products and Toll-like receptor-4 (TLR-4) thereby initiating the intracellular inflammatory signaling cascade (Caseiro et al. 2013). Alpha 2-macroglobulin has been suggested to be a potential biomarker for diabetic retinopathy and other diabetic complications (Lu et al. 2013). Neutrophil elastase was reported to be a marker for the development of diabetic angiopathy (Piwowar et al. 2000). Neutrophil releases neutrophil elastase that enhances inflammatory responses. Alpha-1-antitrypsin (SERPINA1) can suppress apoptosis of pancreatic β-cells that promote insulin secretion (Kalis et al. 2010). A novel immune system regulatory pathway involving SERPINA1 and complement 3 (C3) was unveiled recently (Sahu & Lambris 2001). Activation of C3 promotes phagocytosis, supports local inflammatory responses against pathogens and initiates the humoral immune response; on the other hand, its activation leads to host cell damage. However, binding of SERPINA1 to C3 inhibits and regulates the cleavage and activation of C3 during inflammation. MIF produce by T lymphocytes and macrophage can initiate local inflammation through the inhibition of the random movement of macrophage and enhance their adhesion (Mitamura et al. 2000). Capillary occlusion can be caused by the natural tendency of leucocytes and macrophages to adhere to endothelium that eventually results in retinal ischemia seen in diabetic retinopathy (Schroder et al. 1991). MIF may play a role during the proliferative phase of diabetic retinopathy by activating and retaining intraocular macrophage. Furthermore, MIF interacts with peroxiredoxin-1 by reducing tautomerase and oxidoreductase activities of MIF and inhibits the activity of peroxiredoxin-1 (Kudrin & Ray 2008). Our result show that peroxiredoxin-1 was decreased in NPDR and not found in PDR that was in line with the result reported by Rao et al (Rao et al. 2009).
The up-regulation of BPI fold-containing family A member 1/2, BPI fold-containing family B member 2 and neutrophil gelatinase-associated lipocalin in the PDR patient group suggested that innate immune response might also be involved in PDR. This might also suggest the involvement of microbial agents in PDR pathogenesis. Binding of BPI to endotoxin of Gram-negative bacteria outer membrane could trigger sub-lethal and lethal effects on the bacteria and neutralize the activity of endotoxin (Schultz et al. 2007). Myeloperoxidase (MPO) and lactotransferrin isoform 1 (LTF) are abundantly expressed in neutrophil granulocytes with antioxidant, anticarcinogenic, antibacterial effects, implying an important role in innate immunity. During the oxidative burst of activated neutrophils, MPO utilize hydrogen peroxide and chloride anion to generate a highly reactive and cytotoxic product, hydrochlorous acid which are used by bactericidal (Mutze et al. 2003). Protein-protein networks analysis revealed that cellular target of LTF is MPO, to which LTF bind and inhibit MPO. Neutrophil gelatinase-associated lipocalin was demonstrated to be an early biomarker for diabetic nephropathy (Bolignano et al. 2009). In addition, neutrophil gelatinase-associated lipocalin is an iron-binding protein that may inhibit the growth of bacteria by depleting the iron source of bacteria (Cherayil 2011).

In addition, neutrophil gelatinase-associated lipocalin can also activate pro matrix metalloproteinase-9 (MMP-9) (Tschesche et al. 2001). Hyperglycemia-induced activation of MMP-9 promotes apoptosis of retinal capillary cells and can result in development of diabetic retinopathy (Kowluru 2010). Interestingly, metalloproteinase inhibitor 1, an inhibitor of MMP-9, was found to be increased in both NPDR and PDR patients. In contrast, MMP-9 was low in XDR patients. Florys et al (Florys et al. 2006) reported that high blood glucose concentration could induce the expression of metalloproteinase inhibitor 1. Thus, our results suggest that metalloproteinase inhibitor 1 may influence the development of diabetic retinopathy and combined with high levels of MMP-9 may drive the progression towards the proliferative phase.

The retina is rich in unsaturated fatty acid, rapid oxygen uptake and glucose oxidation rate compared to other areas of the human body that renders the retina highly susceptible to oxidative stress. Heme is highly toxic due to its ability to cause protein aggregation and produce lipid peroxide from lipid peroxidation that could contribute to oxidative stress. Hemopexin functions as a scavenger of heme. The finding of high level of hemopexin in the saliva of PDR patients supported the hypothesis that hyperglycemia, changes in the redox homeostasis and oxidative stress are key pathogenic events in diabetic retinopathy (Kowluru & Chan 2007). Glycation end-products (AGEs) are produced by non-enzymatic glycation reactions of amino groups, lipids and DNA with glucose and its formation is an important pathogenic mechanism in diabetic retinopathy. AGEs have been linked to the breakdown of the inner blood retina barrier (iBRB) during diabetic retinopathy by modulating the expression of vasopermeability factor (Amin et al. 1997). Galectin-3-binding protein, an AGE-binding protein, can enhance the iBRB dysfunction in diabetes and play a significant role in AGE-related pathophysiology during diabetic retinopathy (Pugliese et al. 2000). Galectin-3-binding protein was also presented in relatively high abundance in PDR patients. High abundance of clusterin has been reported in vitreous humor of PDR patients (Gao et al. 2008). Thus, it is not surprising that our data also shows an unprecedented high abundance of clusterin in the saliva of PDR patients. Clusterin is believed to promote angiogenesis or vascular permeability, which contributes to the pathogenesis of diabetic retinopathy (Wang et al. 2013).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), alpha-enolase isoform 1 (ENO1) and pyruvate kinase isozymes M1/M2 isoform c (PKM) are typical enzymes found in saliva that are involved in glycolysis and gluconeogenesis. Although GAPDH is a glycolytic enzyme, it has also been proven to have multiple cytoplasmic, membrane, and nuclear functions. Saunders et al (Saunders et al. 1997) reported that GAPDH was a major intracellular messenger mediating apoptosis of cells and GAPDH translocation to the nucleus was considered a crucial step in glucose-induced apoptosis of retinal Muller cells. Moreover, the role of GADPH in the development and progression of diabetic retinopathy has been investigated by Kanwar & Kowluru (Kanwar & Kowluru 2009).

LXR/RXR activation, FXR/RXR activation, clathrin-mediated endocytosis signaling, acute phase response signaling and regulation of actin-based motility by Rho are highly associated with the pathogenesis and progression of diabetic retinopathy. Activation of liver X receptor (LXR) promotes reverse cholesterol transport and suppressed inflammatory response which in turn improve and inhibit the progression of diabetic retinopathy (Hazra et al. 2012). Retinoid X receptor (RXR) is known to be associated with the progression of diabetic retinopathy (Roy et al. 2009), with RXR activation playing a key role in inhibiting high-glucose-induced oxidative stress, systemic lipid and glucose metabolism, energy homeostasis, and inflammatory control. Role of farnesoid X receptor (FXR) in relation to diabetic retinopathy had not been reported so far, however, the role of FXR in diabetic nephropathy (Wang et al. 2010) and atherosclerotic lesion formation (Hartman et al. 2009) were well established. FXR is involved in microvascular or macrovascular complication of diabetes; hence, FXR may be related to the pathogenesis of diabetic retinopathy. Clathrin-mediated endocytosis is involved in the internalization of the ligand-receptor complex through clathrin-coated vesicles that initialize the intracellular signal transduction cascade in response to the stimulus. AGEs are known to accumulate within the neural retina of diabetics but the effect on neural dysfunction and depletion during retinopathy was poorly investigated (Stitt 2003). Retinal microvascular endothelial cells express AGE-receptor and mediate endocytic uptake of AGEs eventually leads to increased retinal vascular cells toxicity, affecting capillary function (Stitt 2003). Mizuno et al (Mizuno et al. 2010) reported that cellular degeneration, remodeling and cell death leading to emerging of new blood vessels which was observed in PDR was the consequence of excessive glutamate uptake by retinal vascular endothelial cells. As expected, acute phase response signaling pathway had played a causative role in the pathogenesis of diabetic retinopathy. Acute phase response is generally considered an adaptive response that restores homeostasis. However, excessive or persistent overexpression of acute-phase proteins can lead to tissue and organ damage (Gerhardinger et al. 2005). GTPases of the Rho family regulate the interaction between cells and extracellular matrix resulting in angiogenesis, vascular permeability, leukocyte migration and platelet formation in vivo. In the early stage of angiogenesis, GTPase Rho facilitates the endothelial cell retraction and release of junctional complex simultaneously further facilitating the vascular leakage (Cheresh & Stupack 2008). Neovascularization is the main event in the proliferative stage of diabetic retinopathy and GTPase Rho may be a key regulator enzyme in the early stage of angiogenesis. Comparing this profile of vitreous (Gao et al. 2008; Wang et al. 2013; Yamane et al. 2003; Yu et al. 2008), similarities were noted in Table 2. This demonstrates that local (vitreous) changes in protein levels associated with pathogenesis and progression of diabetic retinopathy may be reflected systemically in the saliva.
As other microvascular complications of diabetes also progress with inflammatory processes, serum creatinine was measured (Table 1) to exclude patients with severe diabetic nephropathy. However, patients with non-detectable microvascular complications were not excluded, which is a limitation of our study. Furthermore, although patients with detectable poor oral hygiene were excluded, it is not possible to rule out patients with mild salivary gland inflammation.

In conclusion, the progression from non-proliferative to proliferative retinopathy in type-2 diabetic patients is a complex multi-mechanism and systemic process (Fig 4). These proteins may also be potential salivary biomarkers that correlate with progressive stages of diabetic retinopathy. Thus, saliva may be a convenient and less invasive alternative sample to vitreous humor, tear and serum for diabetic retinopathy protein biomarker development.

Table 2 Proteins associated with NPDR and PDR that were reported in vitreous.

Fig. 4 Summary of pathogenetic mechanism for non-proliferative diabetic retinopathy and proliferative diabetic retinopathy and the functional pathways involved.

Acknowledgement

The authors would like to thank Mr. HT Cheah (Engineer of Orbitrap fusion tribrid mass spectrometer) for his technical assistance with mass spectrometer setting, optimization, and data analysis.
References

Amin RH, Frank RN, Kennedy A, Eliott D, Puklin JE, Abrams GW. 1997. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Investigative Ophthalmology & Visual Science 38(1):36-47.

Bolignano D, Lacquaniti A, Coppolino G, Donato V, Fazio MR, Nicocia G, Buemi M. 2009. Neutrophil Gelatinase-Associated Lipocalin as an Early Biomarker of Nephropathy in Diabetic Patients. Kidney & Blood Pressure Research 32(2):91-98. doi: 10.1159/000209379.

Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72:248-254.

Cabras T, Pisano E, Mastini A, Denotti G, Pusceddu PP, Inzitari R, Fanali C, Nemolato S, Castagnola M, Messana I. 2010. Alterations of the Salivary Secretory Peptidome Profile in Children Affected by Type 1 Diabetes. Molecular & Cellular Proteomics 9(10):2099-2108. doi: 10.1074/mcp.M110.001057.

Caporossi L, Santoro A, Papaleo B. 2010. Saliva as an analytical matrix: state of the art and application for biomonitoring. Biomarkers 15(6):475-487. doi: 10.3109/1354750X.2010.481364.

Casado-Vela J, Martínez-Esteso MJ, Rodriguez E, Borrás E, Elortza F, Bru-Martínez R. 2010. iTRAQ-based quantitative analysis of protein mixtures with large fold change and dynamic range. Proteomics 10(2):343-347. doi: 10.1002/pmic.200900509.

Caseiro A, Ferreira R, Padrao A, Quintaneiro C, Pereira A, Marinheiro R, Vitorino R, Amado F. 2013. Salivary proteome and peptidome profiling in type 1 diabetes mellitus using a quantitative approach. Journal of Proteome Research 12(4):1700-1709. doi: 10.1021/pr3010343.

Castagnola M, Picciotti PM, Messana I, Fanali C, Fiorita A, Cabras T, Calo L, Pisano E, Passali GC, Iavarone F, Paludetti G, Scarano E. 2011. Potential applications of human saliva as diagnostic fluid. Acta Otorhinolaryngologica Italica 31(6):347-357.

Cherayil BJ. 2011. The role of iron in the immune response to bacterial infection. Immunologic Research 50(1):1-9. doi: 10.1007/s12026-010-8199-1.

Cheresh DA, Stupack DG. 2008. Regulation of angiogenesis: apoptotic cues from the ECM. Oncogene 27(48):6285-6298. doi: 10.1038/onc.2008.304.

Collier A, Jackson M, Bell D, Patrick AW, Matthews DM, Young RJ, Clarke BF, Dawes J. 1989. Neutrophil Activation Detected by Increased Neutrophil Elastase Activity in Type-1 (Insulin-Dependent) Diabetes-Mellitus. Diabetes Research Clinical and Experimental 10(3):135-138.

Csosz E, Boross P, Csutak A, Berta A, Toth F, Poliska S, Tork Z, Toszer J. 2012. Quantitative analysis of proteins in the tear fluid of patients with diabetic retinopathy. Journal of Proteomics 75(7):2196-2204. doi: 10.1016/j.jprot.2012.01.019.

Fernández-Real JM, Pickup JC. 2008. Innate immunity, insulin resistance and type 2 diabetes. Trends in Endocrinology and Metabolism 19(1):10-16. doi: 10.1016/j.tem.2007.10.004.

Florys B, Glowińska B, Urban M, Peczynska J. 2006. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes]. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw 12:(3)184-189.

Gao BB, Chen XH, Timothy N, Aiello LP, Feener EP. 2008. Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy. Journal of Proteome Research 7(6):2516-2525. doi: 10.1021/pr800112g.

Gerhardinger C, Costa MB, Coulombe MC, Toth I, Hoehn T, Grosu P. 2005. Expression of acute-phase response proteins in retinal Muller cells in diabetes. Investigative Ophthalmology & Visual Science 46(1):349-357. doi: 10.1167/iovs.04-0860
Giusti L, Baldini C, Bazzichi L, Ciregia F, Tonazzini I, Mascia G, Giannaccini G, Bombardieri S, Lucacchini A. 2007a. Proteome analysis of whole saliva: a new tool for rheumatic diseases—the example of Sjögren's syndrome. *Proteomics* 7(10):1634–1643.

Giusti L, Bazzichi L, Baldini C, Ciregia F, Mascia G, Giannaccini G, Del Rosso M, Bombardieri S, Lucacchini A. 2007b. Specific proteins identified in whole saliva from patients with diffuse systemic sclerosis. *The Journal of Rheumatology* 34(10):2063–2069.

Good DM, Thongboonkerd V, Novak J, Bascands JL, Schanstra JP, Coon JJ, Dominiczak A, Mischak H. 2007. Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. *Journal of Proteome Research* 6(12):4549–4555.

Hartman HB, Gardell SJ, Petucci CJ, Wang SG, Krueger JA, Evans MJ. 2009. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE(-/-) mice. *Journal of Lipid Research* 50(6):1090-1100. doi: 10.1194/jlr.M800619-JLR200.

Hazra S, Rasheed A, Bhatwadekar A, Wang XX, Shaw LC, Patell M, Caballero S, Magomedova L, Solis N, Yan YQ, Wang WD, Thinschmidt JS, Verma A, Li QH, Levi M, Cummins CL, Grant MB. 2012. Liver X Receptor Modulates Diabetic Retinopathy Outcome in a Mouse Model of Streptozotocin-Induced Diabetes. *Diabetes* 61(12):3270-3279. doi: 10.2337/db11-1596.

Hu S, Wang J, Meijer J, Leong S, Xie Y, Yu T, Zhou H, Henry S, Vissink A, Pijpe J, Kallenberg C, Elashoff D, Loo JA, Wong DT. 2007b. Salivary proteomic and genomic biomarkers for primary Sjögren's syndrome. *Arthritis Rheumatism* 56(11):3588–3600.

Hu S, Loo JA, Wong DT. 2007a. Human saliva proteome analysis and disease biomarker discovery. *Expert Review of Proteomics* 4(4):531–538.

Kanwar M, Kowluru RA. 2009. Role of Glyceraldehyde 3-Phosphate Dehydrogenase in the Development and Progression of Diabetic Retinopathy. *Diabetes* 58(1):227-234. doi: 10.2337/db08-1025.

Kowluru RA. 2010. Role of Matrix Metalloproteinase-9 in the Development of Diabetic Retinopathy and Its Regulation by H-Ras. *Investigative Ophthalmology & Visual Science* 51(8):4320-4326. doi: 10.1167/iovs.09-4851.

Kowluru RA, Chan PS. 2007. Oxidative Stress and Diabetic Retinopathy. *Experimental Diabetes Research* 2007:43603. doi: 10.1155/2007/43603.

Kudrin A, Ray D. 2008. Cunning factor: macrophage migration inhibitory factor as a redox-regulated target. *Immunology and Cell Biology* 86(3):232-238. doi: 10.1038/sj.icb.7100133.

Lee JM, Garon E, Wong DT. 2009. Salivary diagnostics. *Orthodontics and Craniofacial Research* 12(3):206–211. doi: 10.1111/j.1601-6343.2009.01454.x.

Lu CH, Lin ST, Chou HC, Lee YR, Chan HL. 2013. Proteomic analysis of retinopathy-related plasma biomarkers in diabetic patients. *Archives of Biochemistry and Biophysics* 529(2):146-156. doi: 10.1016/j.abb.2012.11.004.
Mitamura Y, Takeuchi S, Matsuda A, Tagawa Y, Mizue Y, Nishihira J. 2000. Macrophage migration inhibitory factor levels in the vitreous of patients with proliferative diabetic retinopathy. *British Journal of Ophthalmology* 84(6):636-639. Doi 10.1136/Bjo.84.6.636.

Mizuno F, Barabas P, Krizaj D, Akopian A. 2010. Glutamate-induced internalization of Ca(v)1.3 L-type Ca2+ channels protects retinal neurons against excitotoxicity. *The Journal of Physiology* 588(Pt 6):953-966. doi: 10.1113/jphysiol.2009.181305.

Mütze S, Hebling U, Stremmel W, Wang J, Arnhold J, Pantopoulos K, Mueller S. 2003. Myeloperoxidase-derived hypochlorous acid antagonizes the oxidative stress-mediated activation of iron regulatory protein 1. *Journal of Biological Chemistry* 278(42):40542-40549. doi: 10.1074/jbc.M307159200.

Peluso G, De Santis M, Inzitari R, Fanali C, Cabras T, Messana I, Castagnola M, Ferraccioli GF. 2007. Proteomic study of salivary peptides and proteins in patients with Sjögren's syndrome before and after pilocarpine treatment. *Arthritis and Rheumatism*. 56(7):2216–2222.

Piwowar A, Knapik-Kordecka M, Warwas M. 2000. Concentration of leukocyte elastase in plasma and polymorphonuclear neutrophil extracts in type 2 diabetes. *Clinical Chemistry and Laboratory Medicine* 38(12):1257-1261. doi: 10.1515/Cclm.2000.198.

Pugliese G, Prici F, Leto G, Amadio I, Iacobini C, Romeo G, Lenti L, Sale P, Gradini R, Liu FT, Di Mario U. 2000. The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression. *Diabetes* 49(7):1249-1257. doi: 10.2337/diabetes.49.7.1249.

Rao PV, Reddy AP, Lu X, Dasari S, Krishnaprasad A, Biggs E, Roberts CT, Nagalla SR. 2009. Proteomic identification of salivary biomarkers of type-2 diabetes. *Journal of Proteome Research* 8(1):239-245. 10.1021/pr8003776

Rauniyar N, Yates JR 3rd. 2014. Isobaric labeling-based relative quantification in shotgun proteomics. *Journal of Proteome Research* 13(12):5293-309. doi: 10.1021/pr500880b.

Reutens AT, Bonnet F, Lantieri O, Roussel R, Balkau B, Epidemiological Study on the Insulin Resistance Syndrome Study Group. 2013. The association between cystatin C and incident type 2 diabetes is related to central adiposity. *Nephrology, Dialysis, Transplantation* 28(7):1820-1829. doi: 10.1093/ndt/gfs561.

Ross PL, Huang YLN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, Purkayastha S, Juhasz P, Martin S, Bartlet-Jones M, He F, Jacobson A, Pappin DJ. 2004. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. *Molecular & Cellular Proteomics* 3(12):1154-1169. doi: 10.1074/mcp.M400129-MCP200.

Roy MS, Hallman M, Fu YP, Machado M, Hanis CL. 2009. Assessment of 193 Candidate Genes for Retinopathy in African Americans With Type 1 Diabetes. *Archives of Ophthalmology* 127(5):605-612. doi: 10.1001/archophthalmol.2009.48.

Sahu A, Lambris JD. 2001. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. *Immunological Reviews* 180:35-48. doi: 10.1034/j.1600-065X.2001.1800103.x

Saunders PA, Chalecka-Franaszek E, Chuang DM. 1997. Subcellular distribution of glyceraldehyde-3-phosphate dehydrogenase in cerebellar granule cells undergoing cytosine arabinoside-induced apoptosis. *Journal of Neurochemistry* 69(5):1820-1828.

Schröder S, Palinski W, Schmid-Schönbein GW. 1991. Activated Monocytes and Granulocytes, Capillary Nonperfusion, and Neovascularization in Diabetic-Retinopathy. *American Journal of Pathology* 139(1):81-100.
Schultz H, Hume J, Zhang DS, Gioanninni TL, Weiss JP. 2007. A novel role for the bactericidal/permeability increasing protein in interactions of gram-negative bacterial outer membrane Blebs with dendritic cells. *Journal of Immunology* 179(4):2477-2484.

Senko, MW, Remes PM, Canterbury JD, Mathur R, Song Q, Eliuk SM, Mullen C, Earley L, Hardman H, Blethrow JD, Bui H, Specht A, Lange O, Denisov E, Makarov A, Horning S, Zakrouskov V. 2013. Novel parallelized quadrupole/linear ion trap/orbitrap trybrid mass spectrometer improves proteome coverage and peptide identification rates. *Analytical Chemistry* 85(24):11710-11714. doi: 10.1021/ac403115c.

Shinkai RSA, Cornell JE, Hatch JP, Yeh CK. 2004. Intraoral tactile sensitivity in adults with diabetes. *Diabetes Care* 27(4):869-873. doi: 10.2337/diacare.27.4.869.

Stitt AW. 2003. The role of advanced glycation in the pathogenesis of diabetic retinopathy. *Experimental and Molecular Pathology* 75(1):95-108. doi: 10.1016/S0014-4800(03)00035-2.

Tashimo A, Mitamura Y, Nagai S, Nakamura Y, Ohtsuka K, Ohtsuka K, Mizue Y, Nishihira J. 2004. Aqueous levels of macrophage migration inhibitory factor and monocyte chemotactic protein-1 in patients with diabetic retinopathy. *Diabetic Medicine* 21(12):1292-1297.

Tarr JM, Kaul K, Chopra M, Kohnem EM, Chibber R. 2013. Pathophysiology of diabetic retinopathy. *ISRN Ophthalmology* 2013:343560. doi: 10.1155/2013/343560.

Tschesche H, Zolzer V, Triebel S, Bartsch S. 2001. The human neutrophil lipocalin supports the allosteric activation of matrix metalloproteinases. *European Journal of Biochemistry* 268(7):1918-1928. doi: 10.1046/j.1432-1327.2001.02066.x.

Vitorino R, Barros AS, Caseiro A, Ferreira R, Amado F. 2012. Evaluation of different extraction procedures for salivary peptide analysis. *Talanta* 94:209-215. doi: 10.1016/j.talanta.2012.03.023.

Vizcaino JA, Csordas A, del-Toro N, Dianes JA, Griss J, Lavadas I, Mayer G, Perez-Riverol Y, Reisinger F, Ternent T, Xu QW, Wang R, Hermjakob H. 2016. 2016 update of the PRIDE database and related tools. *Nucleic Acids Research* 44(D1):D447-D456. doi: 10.1093/nar/gkv1145.

Wang H, Feng L, Hu JW, Xie CL, Wang F. 2013. Differentiating vitreous proteomes in proliferative diabetic retinopathy using high-performance liquid chromatography coupled to tandem mass spectrometry. *Experimental Eye Research* 108:110-119. doi: 10.1016/j.exer.2012.11.023.

Wang XX, Jiang T, Shen Y, Caldas Y, Miyazaki-Anzai S, Santamaria H, Urbanek C, Solis N, Scherzer P, Lewis L, Gonzalez FJ, Adorini L, Pruzanski M, Kopp JB, Verlander JW, Levi M. 2010. Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model. *Diabetes* 59(11):2916-2927. doi: 10.2337/Db10-0019.

Wilkinson CP, Ferris FL, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Parrajassegaram R, Verdaguer JT, Global Diabetic Retinopathy Project Group. 2003. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. *Ophthalmology* 110(9):1677-1682. doi: 10.1016/S0161-6420(03)00475-5.

Yamane K, Minamoto A, Yamashita H, Takamura H, Miyamoto-Moiken Y, Yoshizato K, Nabetani T, Tsugita A, Mishima HK. 2003. Proteome analysis of human vitreous proteins. *Molecular & Cellular Proteomics* 2(11):1177-1187. doi: 10.1074/mcp.M300038-MCP200.

Yu J, Liu F, Cui SJ, Liu Y, Song ZY, Cao H, Chen FE, Wang WJ, Sun T, Wang F. 2008. Vitreous proteomic analysis of proliferative vitreoretinopathy. *Proteomics* 8(17):3667-3678. doi: 10.1002/pmic.200700824.
Supplementary figures

S1 figure. Gene ontology (GO) classification of 315 salivary proteins identified in this study. The proteins were classified based on (A) subcellular localization, (B) biological processes involved and (C) molecular functions.

S2 figure. Gene ontology (GO) classification of top 20 up-regulated salivary proteins identified in this study. The proteins were classified based on (A) subcellular localization, (B) biological processes involved and (C) molecular functions.

S3 figure. Protein-protein interaction network prediction. Network (A) contains 35 proteins involved in connective tissue disorders, immunological disease and inflammatory disease in which 22 proteins were identified from the NPDR disease group. Network (B) contains 35 proteins involved in cellular movement, hematological system development and function and immune cell trafficking in which 28 proteins are identified from the PDR disease group. Network (C) contains 26 proteins involved in cellular growth and proliferation, cancer and carbohydrate metabolism in which 10 proteins are identified in PDR disease group. (ACTB = actin, cytoplasmic 1, ANXA1 = annexin A1, APOA1 = apolipoprotein A-I, CAMP = cathelicidin antimicrobial peptide, CAP1 = adenyl cyclase-associated protein 1, CLU = clusterin, C3 = complement C3, ELANE = neutrophil elastase, ENO1 = alpha-enolase isoform 1, EZR = ezrin, GAPDH = glyceraldehyde-3-phosphate dehydrogenase isoform 2, GSN = gelsolin isoform d, HBA1/HBA2 = hemoglobin subunit alpha, HP = haptoglobin isoform 2, HSPA8 = heat shock cognate 71 kDa protein isoform 1, HSPA1A/HSPA1B = heat shock 70 kDa protein 1A/1B, LCP1 = plastin-2, LCN1 = lipocalin-1 isoform 1, LCN2 = neutrophil gelatinase-associated lipocalin, LDHA = L-lactate dehydrogenase A chain isoform 3, LTF = lactotransferrin isoform 1, MIF = macrophage migration inhibitory factor, MMP9 = matrix metalloproteinase-9, MPO = myeloperoxidase, PKM = pyruvate kinase isozymes M1/M2 isoform c, PLTP = phospholipid transfer protein isoform a, PRDX1 = peroxiredoxin-1, PRTN3 = profilin-1, SERPINA1 = alpha-1-antitrypsin, SLPI = antileukoproteinase, S100A8 = protein S100-A8, S100A9 = protein S100-A9, TIMP1 = metalloproteinase inhibitor 1, TPM3 = tropomyosin alpha-3 chain isoform 2)

Supplementary tables

S1 table. Salivary proteins that are differentially expressed in PDR disease group compared to XDR disease group.
S2 table. Salivary proteins that are differentially expressed in NPDR patient group compared to XDR patient group.

S3 table. The differentially expressed proteins identified from the study that interact with each other in the protein-protein network analysis.
Table 1 (on next page)

Demographic of subjects.

M, Malays; I, Indian; C, Chinese; F, Female. All the pairs were compared using one-way ANOVA and Student's t-test, there no statistically significant difference (p-value all >0.05)
1 Table 1 Demographic of subjects.

| Parameters                   | XDR (N=15)       | NPDR (N=15)      | PDR (N=15)       |
|------------------------------|-----------------|-----------------|-----------------|
| Age                          | 61.8±8.77       | 60.63±6.49      | 58.94±6.98      |
| Race (M/I/C)                 | 7/3/5           | 7/5/3           | 9/4/2           |
| Sex (Male/F)                 | 5/10            | 7/8             | 8/7             |
| Duration of diabetes (year)  | 12.87±4.97      | 13.94±7.15      | 14.62±5.51      |
| HbA1c (%)                    | 7.73±1.15       | 8.43±1.08       | 8.85±1.9        |
| Fasting blood sugar (mmol/l) | 8.16±1.62       | 8.6±3.37        | 8.99±3.3        |
| Creatinine (µg/l)            | 93.9±41.17      | 107.0±40.9      | 125.3±71.86     |

M, Malays; I, Indian; C, Chinese; F, Female.
All the pairs were compared using ANOVA and T-test, there no statistically significant difference (p-value all >0.05)
Table 2 (on next page)

Proteins associated with NPDR and PDR that were reported in vitreous.
Table 2 Proteins associated with NPDR and PDR that were reported in vitreous.

| Protein name                        | Saliva          | Vitreous                                                                                                                           |
|-------------------------------------|-----------------|-----------------------------------------------------------------------------------------------------------------------------------|
| Alpha-1-antitrypsin (SERPINA1)      | Elevated in PDR | Elevated in moderate and severe PDR (Gao et al. 2008; Kanwar et al. 2009; Hazra et al. 2012)                                      |
| Alpha-2-macroglobulin               | Elevated in PDR | Elevated in severe PDR (Gao et al. 2008; Kanwar et al. 2009; Hazra et al. 2012)                                               |
| Alpha-enolase                       | Elevated in PDR | Present in control and moderate PDR (Kanwar et al. 2009; Hazra et al. 2012)                                                  |
| Apolipoprotein A-I                  | Elevated in PDR | Elevated in moderate and severe PDR (Gao et al. 2008; Kanwar et al. 2009; Hazra et al. 2012)                                |
| Catalase                            | Elevated in PDR | Present in XDR and PDR (Gao et al. 2008; Kanwar et al. 2009)                                                                  |
| Clusterin                           | Elevated in PDR | Present in vitreous (esp. moderate and severe PDR (Gao et al. 2008; Hazra et al. 2012); decreased in PDR (Kadoglou et al. 2005) |
| Complement C3                       | Elevated in PDR | Elevated in moderate PDR (Gao et al. 2008; Hazra et al. 2012)                                                                  |
| Cystatin-C                          | Elevated in PDR | Present in vitreous (control, moderate and severe PDR) (Gao et al. 2008; Hazra et al. 2012)                                   |
| Fructose-bisphosphate aldolase C    | Elevated in PDR | Present in XDR (Gao et al. 2008)                                                                                             |
| Galectin-3-binding protein          | Elevated in PDR | Elevated in severe PDR (Gao et al. 2008; Hazra et al. 2012)                                                                  |
| Gelsolin                            | Elevated in PDR | Present in moderate and severe PDR (Hazra et al. 2012)                                                                          |
| Glyceraldehyde-3-phosphate dehydrogenase | Elevated in PDR | Decreased in PDR (Kadoglou et al. 2005); present in control and moderate PDR (Hazra et al. 2012)                             |
| Haptoglobin                         | Elevated in PDR | Present in vitreous (esp. severe PDR) (Gao et al. 2008; Kanwar et al. 2009; Hazra et al. 2012)                               |
| Hemoglobin subunit alpha            | Elevated in PDR | Elevated in PDR (Gao et al. 2008)                                                                                             |
| Hemopexin                           | Elevated in PDR | Elevated in XDR (Gao et al. 2008; Kadoglou et al. 2005),32]; present in control, moderate and severe PDR (Kanwar et al. 2009; Hazra et al. 2012) |
| Peroxiredoxin-1                     | Decreased in NPDR | Elevated in PDR (Gao et al. 2008); present in control (Hazra et al. 2012)                                                   |
| Protein S100-A8                     | Elevated in PDR | Present in XDR and PDR (Gao et al. 2008)                                                                                       |
| Protein S100-A9                     | Elevated in PDR | Present in XDR and PDR (Gao et al. 2008)                                                                                       |
Log ratio of relative intensity (NPDR/XDR; PDR/XDR) for proteins commonly found in XDR, NPDR and PDR disease groups.
| Gene Name                                      | Sift Score | Log Ratio |
|-----------------------------------------------|------------|-----------|
| keratin, type II cytoskeletal 6A [Homo sapiens]| 0.67       | 0.03      |
| histone H2A type 8 [Homo sapiens]             | 0.72       | 0.05      |
| alpha-amylase 2B precursor [Homo sapiens]     | 0.74       | 0.06      |
| superoxide dismutase 1 precursor [Homo sapiens]| 0.84   | 0.09      |
| TMEM199-UBE2Y1 fusion protein [Homo sapiens]  | 0.86       | 0.10      |
| actin, alpha skeletal muscle [Homo sapiens]   | 0.87       | 0.10      |
| keratin, type II cytoskeletal 5 [Homo sapiens]| 0.88       | 0.11      |
| proline-rich protein 4 isoform 2 precursor [Homo sapiens]| 0.90 | 0.12      |
| ubiquitin-60S ribosomal protein U40 precursor [Homo sapiens]| 0.90 | 0.12      |
| alpha-1-acid glycoprotein 2 precursor [Homo sapiens]| 0.91 | 0.12      |
| neutrophil defensin 1 precursor [Homo sapiens]| 0.92       | 0.13      |
| metalloprotease inhibitor 3 precursor [Homo sapiens]| 0.93 | 0.13      |
| hemoglobin subunit alpha [Homo sapiens]       | 0.94       | 0.13      |
| glyceroldehyde-3-phosphate dehydrogenase isoform 2 [Homo sapiens]| 0.95       | 0.13      |
| phosphoglycerate mutase 1 [Homo sapiens]      | 0.96       | 0.14      |
| pyruvate kinase isozymes M1/M2 isomeric c [Homo sapiens]| 0.97 | 0.14      |
| cystatin-5 precursor [Homo sapiens]           | 0.98       | 0.14      |
| UPP0762 protein G60F58 precursor [Homo sapiens]| 0.99 | 0.14      |
| cystatin-B [Homo sapiens]                     | 1.00       | 0.14      |
| apolipoprotein A-I [Homo sapiens]             | 1.00       | 0.14      |
| glutathione S-transferase P [Homo sapiens]    | 1.00       | 0.14      |
| cystatin-SA precursor [Homo sapiens]          | 1.00       | 0.14      |
| fructose-bisphosphate aldolase A isoform 2 [Homo sapiens]| 1.01 | 0.14      |
| hemoglobin subunit beta [Homo sapiens]        | 1.01       | 0.14      |
| protein S100-A8 [Homo sapiens]                | 1.02       | 0.15      |
| actin, cytoplasmic 1 [Homo sapiens]           | 1.03       | 0.15      |
| immunoglobulin 1 chain precursor [Homo sapiens]| 1.03 | 0.15      |
| lipocalin-1 isoform 1 precursor [Homo sapiens]| 1.04       | 0.15      |
| alpha-amylose 1 precursor [Homo sapiens]      | 1.04       | 0.15      |
| zymogen granule protein 16 homolog B precursor [Homo sapiens]| 1.05 | 0.16      |
| keratin, type I cytoskeletal 13 isoform a [Homo sapiens]| 1.05 | 0.16      |
| kallikrein-1 precursor [Homo sapiens]         | 1.06       | 0.16      |
| transketolase isoform 1 [Homo sapiens]        | 1.06       | 0.16      |
| BPI fold-containing family B member 2 precursor [Homo sapiens]| 1.06 | 0.16      |
| glucose-6-phosphate isomerase isoform 1 [Homo sapiens]| 1.07 | 0.17      |
| prolactin-inducible protein precursor [Homo sapiens]| 1.07 | 0.17      |
| keratin, type I cytoskeletal 1D [Homo sapiens]| 1.08       | 0.17      |
| carbonic anhydrase 6 isoform 1 precursor [Homo sapiens]| 1.08 | 0.17      |
| keratin, type II cytoskeletal 4 [Homo sapiens]| 1.08       | 0.17      |
| heat shock 70 kDa protein 1A/1B precursor [Homo sapiens]| 1.09 | 0.17      |
| serotransferrin precursor [Homo sapiens]      | 1.09       | 0.17      |
| lactoperoxidase isoform 1 precursor [Homo sapiens]| 1.10       | 0.18      |
| zinc-alpha-2-glycoprotein precursor [Homo sapiens]| 1.10 | 0.18      |
| deleted in malignant brain tumors 1 protein isoform c precursor [Homo sapiens]| 1.10 | 0.18      |
| polymeric immunoglobulin receptor precursor [Homo sapiens]| 1.11 | 0.19      |
| serum albumin precursor [Homo sapiens]        | 1.11       | 0.19      |
| mucus-5B precursor [Homo sapiens]             | 1.12       | 0.19      |
| keratin, type I cytoskeletal 16 [Homo sapiens]| 1.12       | 0.19      |
| macrophage migration inhibitory factor [Homo sapiens]| 1.12 | 0.19      |
| aldehyde dehydrogenase, dimeric NADP-prefering [Homo sapiens]| 1.13 | 0.20      |
| vitamin D-binding protein isoform 3 precursor [Homo sapiens]| 1.13 | 0.20      |
| cathepsin [Homo sapiens]                      | 1.13       | 0.20      |
| desmoglein-3 precursor [Homo sapiens]         | 1.13       | 0.20      |
| alpha-1-antitrypsin precursor [Homo sapiens]  | 1.14       | 0.20      |
| transaldolase [Homo sapiens]                  | 1.14       | 0.20      |
| histone H3.2 [Homo sapiens]                   | 1.14       | 0.20      |
| phospholipid transfer protein isoform a precursor [Homo sapiens]| 1.14 | 0.20      |
| gelatin isoform 1 [Homo sapiens]              | 1.15       | 0.20      |
| 14-3-3 protein sigma [Homo sapiens]           | 1.15       | 0.20      |
| myeloperoxidase precursor [Homo sapiens]      | 1.15       | 0.20      |
| myeloblastin precursor [Homo sapiens]         | 1.15       | 0.20      |
| lysosome C precursor [Homo sapiens]           | 1.15       | 0.20      |
| triosephosphate isomerase isoform 2 [Homo sapiens]| 1.16 | 0.21      |
| alpha-actinin-1 isoform c [Homo sapiens]      | 1.16       | 0.21      |
| neutrophil elastase precursor [Homo sapiens]  | 1.16       | 0.21      |
| cathepsin precursor [Homo sapiens]            | 1.16       | 0.21      |
| cystatin-C precursor [Homo sapiens]           | 1.16       | 0.21      |
| heat shock cognate 71 kDa protein isoform 1 [Homo sapiens]| 1.17 | 0.21      |
| matrix metalloproteinase-9 precursor [Homo sapiens]| 1.17 | 0.21      |
| protein disulfide-isomerase precursor [Homo sapiens]| 1.18 | 0.22      |
| protein S100-A9 [Homo sapiens]                | 1.18       | 0.22      |
| haptoglobin isoform 2 precursor [Homo sapiens]| 1.18       | 0.22      |
| BPI fold-containing family A member 2 precursor [Homo sapiens]| 1.19 | 0.22      |
| alpha-1-antitrypsin precursor [Homo sapiens]  | 1.19       | 0.22      |
| annexin A1 [Homo sapiens]                     | 1.19       | 0.22      |
| 6-phosphogluconate dehydrogenase, decarboxylating [Homo sapiens]| 1.19 | 0.22      |
| BPI fold-containing family B member 1 precursor [Homo sapiens]| 1.19 | 0.22      |
| alpha-2-macroglobulin-like protein 1 precursor [Homo sapiens]| 1.20 | 0.23      |
| plasmin-2 [Homo sapiens]                      | 1.20       | 0.23      |
| lactotransferrin isoform 1 precursor [Homo sapiens]| 1.20 | 0.23      |

- The table lists various genes with their respective Sift scores and log ratios.
- The log ratio indicates the relative expression level of each gene.
- The genes are sorted by their log ratio values.
Log ratio of relative intensity (NPDR/XDR; PDR/XDR or proteins found exclusively in NPDR and PDR disease groups.)
3

Canonical pathways comparative studies in differentially expressed proteins from NPDR and PDR groups.
Summary of pathogenetic mechanism for non-proliferative diabetic retinopathy and proliferative diabetic retinopathy and the functional pathways involved.
Non-proliferative diabetic retinopathy → Disease progression → Proliferative diabetic retinopathy

**Vascular Permeability**
- Leukocyte extravasation signalling
- Regulation of actin-based motility by Rho
- Actin cytoskeleton signalling

**Inflammation**
- Acute phase signalling
- IL-12 signalling and production in macrophage

**Oxidative stress**
- Production of nitric oxide and reactive oxygen species in macrophage

**Lipid exudation**
- LXR/RXR activation
- FXR/RXR activation

**Hyperglycemia**
- Glycolysis 1
- Gluconeogenesis

**Advanced glycation end-product**
- Clathrin-mediated endocytosis signalling

**Retinal ischemia**
- Clathrin mediated endocytosis signalling
- IL-12 signalling and production

**Neovascularization**
- Regulation of actin-based motility by Rho
- Actin cytoskeleton signalling